Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis

被引：0
|
作者：
Gary T. Ferguson
Patrick Darken
Shaila Ballal
Mohd Kashif Siddiqui
Barinder Singh
Sumeet Attri
Ulf Holmgren
Enrico de Nigris
机构：
[1] Pulmonary Research Institute of Southeast Michigan,
[2] AstraZeneca,undefined
[3] Parexel International,undefined
[4] AstraZeneca,undefined
[5] AstraZeneca,undefined
来源：
Advances in Therapy | 2020年 / 37卷
关键词：
Chronic obstructive pulmonary disease; Exacerbations; Inhaled corticosteroid; Long-acting muscarinic antagonist; Long-acting β; -agonist; Lung function; Network meta-analysis; Patient-reported outcomes; Triple therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2956 / 2975
页数：19
相关论文
共 42 条
  • [31] Effect of monitoring adherence to regular inhaled corticosteroid (ICS) alone or in combination with a long-acting β2-agonist (LABA) using electronic methods on asthma outcomes: a narrative systematic review
    Almutairi, Mohammed
    Marriott, John F.
    Mansur, Adel
    BMJ OPEN, 2023, 13 (08):
  • [32] Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal
    M. Reza Maleki-Yazdi
    Mathieu Molimard
    Dorothy L. Keininger
    Jean-Bernard Gruenberger
    Joao Carrasco
    Claudia Pitotti
    Elsa Sauvage
    Sara Chehab
    David Price
    Applied Health Economics and Health Policy, 2016, 14 : 579 - 594
  • [33] Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal
    Maleki-Yazdi, M. Reza
    Molimard, Mathieu
    Keininger, Dorothy L.
    Gruenberger, Jean-Bernard
    Carrasco, Joao
    Pitotti, Claudia
    Sauvage, Elsa
    Chehab, Sara
    Price, David
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (05) : 579 - 594
  • [34] Dual bronchodilator versus inhaled corticosteroid/long-acting β2-agonist in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials
    Chen, Hong
    Wang, Ke
    Yuan, Tao
    Wang, Xiaoming
    Huanng, Lan
    Jiang, Zhenhuan
    Chen, Keyang
    Du, Yuejun
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 93
  • [35] Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting β2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
    Mezzi, Karen
    McBryan, Danny
    Pallante, John
    Alagappan, Vijay
    Chen, Hungta
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [36] Once-Daily QVA149 Demonstrates Superior Outcomes in COPD Patients Previously Treated With Fixed-Dose Long-Acting β2-Agonist/Inhaled Corticosteroid (LABA/ICS): The ILLUMINATE Study
    Mezzi, Karen
    Pallante, John
    Alagappan, Vijay
    Chen, Hungta
    Banerji, Donald
    CHEST, 2014, 145 (03)
  • [37] ONCE-DAILY QVA149 DEMONSTRATES SUPERIOR OUTCOMES IN COPD PATIENTS PREVIOUSLY TREATED WITH FIXED-DOSE LONG-ACTING?2-AGONIST/INHALED CORTICOSTEROID (LABA/ICS): THE ILLUMINATE STUDY
    Kwaijtaal, M.
    Mezzi, K.
    Mcbryna, D.
    Pallante, J.
    Alagappan, V
    Banerji, D.
    RESPIROLOGY, 2014, 19 : 116 - 116
  • [38] Extrafine HFA-beclomethasone-formoterol vs. nonextrafine combination of an inhaled corticosteroid and a long acting β2-agonist in patients with persistent asthma: A systematic review and meta-analysis
    Liu, Ting
    Yang, Dan
    Liu, Chuntao
    PLOS ONE, 2021, 16 (09):
  • [39] The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
    Tanimura, Kazuya
    Sato, Susumu
    Fujita, Yukio
    Yamamoto, Yoshifumi
    Hajiro, Takashi
    Horita, Nobuyuki
    Kawayama, Tomotaka
    Muro, Shigeo
    CHRONIC RESPIRATORY DISEASE, 2023, 20
  • [40] Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial
    Jinping Zheng
    Simonetta Baldi
    Li Zhao
    Huiping Li
    Kwan-Ho Lee
    Dave Singh
    Alberto Papi
    Frédérique Grapin
    Alessandro Guasconi
    George Georges
    Respiratory Research, 22
12345